January 16, 2023
The new article “Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study” by Dmitry Shchelokov and Oleg Demin Jr was published in mAbs journal at the end of December 2022.
Oleg Demin Jr comments on the article, “Mechanistic description of biomarkers and endpoints is necessary for accurate analysis of the clinical trial results and prediction of these outcomes by QSP modeling. One of these endpoints is target receptor occupancy which is measured in early clinical trials for therapeutic antibodies including monoclonal and bispecific ones, etc. In the published article we have shown that the method of target occupancy measurement can affect the results of clinical trials and their interpretation”.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | August 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
1.
02 Aug 2021 16:17
InSysBio to take part in PharmSci360 2021
InSysBio announces its participation in AAPS 2021 PHARMSCI 360 which is to be held in Pennsylvania Convention Center, Philadelphia, PA, and Online 17-20 October, 2021. InSysBio team is going to present the update at the Virtual Booth (VB1) and 2 posters in frames of the Conference
|
3
|
4
|
5
|
6
1.
06 Aug 2021 15:38
InSysBio to participate in Biomarkers for Alzheimer’s Disease Summit
InSysBio will take part in Annual Biomarkers for Alzheimer’s Disease Summit, Digital Event which is going to be held August 24-26, 2021. InSysBio will present its Neurodegeneration modeling issues and Alzheimer’s Disease Platform update at its Virtual Booth! Moreover, Tatiana Karelina, Head of Neurodegenerative Diseases Modeling Team, will give a talk
|
7
|
8
|
|
9
|
10
|
11
1.
11 Aug 2021 15:50
InSysBio to launch its OpenSource HetaSimulator project
The new platform is a part of Heta-based QSP modeling infrastructure
[Moscow – 11.08.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, now presents HetaSimulator. It is a part of Heta project that embraces three components. HetaSimulator is an OpenSource simulation and parameters estimation platform for the Heta modeling language.
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
1.
18 Aug 2021 10:49
InSysBio to take part in PAGE 2021
InSysBio announces its participation in PAGE 2021 Online meeting which is to be held on the 2nd, 3rd, 6th, and 7th of September 2021. InSysBio team is going to present its latest development at the Virtual Exhibition e-booth and six posters
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||
Thank you for your message! We will get back to you shortly.
